tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Imunon, Inc. Advances COVID-19 Vaccine Research with IMNN-101 Study Completion

Imunon, Inc. Advances COVID-19 Vaccine Research with IMNN-101 Study Completion

Imunon, Inc. ((IMNN)) announced an update on their ongoing clinical study.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Study Overview: Imunon, Inc. has completed a Phase 1/2 study titled Phase 1/2, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of a DNA Vaccine, IMNN-101, Administered as a Single Dose in Healthy Adults Previously Vaccinated Against SARS-CoV-2. The study aimed to assess the safety and immune response of the IMNN-101 vaccine, which is significant in advancing COVID-19 vaccination strategies.

Intervention/Treatment: The study tested IMNN-101, a DNA vaccine designed to target the SARS-CoV-2 Omicron XBB.1.5 spike antigen. It is administered as a single intramuscular dose and formulated with Crown poloxamer and AlPO4 as adjuvants.

Study Design: This interventional study followed a single-group model with no masking, focusing on prevention. Participants received varying doses of IMNN-101, and the study proceeded in a staged manner to ensure safety.

Study Timeline: The study began on June 4, 2024, and was last updated on July 22, 2025. These dates are crucial as they mark the study’s progression and recent updates.

Market Implications: The completion of this study could positively impact Imunon, Inc.’s stock performance by enhancing investor confidence in its vaccine pipeline. As the COVID-19 vaccine market remains competitive, successful results could position Imunon favorably against competitors.

The study is ongoing, with further details available on the ClinicalTrials portal.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1